Deciphera Pharmaceuticals Gets $2.4 Billion Buyout Offer From ONO Pharmaceutical
By Chris Wack
Deciphera Pharmaceuticals is being bought by ONO Pharmaceutical for $25.60 a share in cash through a tender offer with a total equity value of $2.4 billion.
Deciphera shares are halted at $14.65 in premarket trading.
At the close of the transaction, Deciphera will be merged with a wholly-owned subsidiary of ONO. The boards of directors of both companies have unanimously approved the transaction.
The purchase price represents a premium of 74.7% to Deciphera's closing share price of $14.65 on Friday, and a premium of 68.8% to Deciphera's 30-trading-day volume weighted average price as of Friday.
The acquisition is expected to close in the third quarter of 2024.
Upon completion, Deciphera will operate as a standalone business of ONO Group, from its headquarters in Waltham, Mass.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
April 29, 2024 07:32 ET (11:32 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks